GW Pharmaceuticals PLC- (GWPH) Shares Gap Up to $82.73
Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) gapped up before the market opened on Tuesday . The stock had previously closed at $82.62, but opened at $82.73. GW Pharmaceuticals PLC- shares last traded at $84.66, with a volume of 185,364 shares traded.
GWPH has been the topic of several research reports. Piper Jaffray Cos. restated a “buy” rating and set a $147.00 price target on shares of GW Pharmaceuticals PLC- in a research note on Sunday, June 26th. Cowen and Company restated a “buy” rating and set a $135.00 price target on shares of GW Pharmaceuticals PLC- in a research note on Monday, June 27th. Vetr upgraded GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating and set a $91.16 price target on the stock in a research note on Wednesday, July 13th. Zacks Investment Research upgraded GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $108.00 price target on the stock in a research note on Tuesday, July 5th. Finally, Morgan Stanley raised their price target on GW Pharmaceuticals PLC- from $149.00 to $152.00 and gave the company an “overweight” rating in a research note on Tuesday, June 28th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. GW Pharmaceuticals PLC- has a consensus rating of “Buy” and an average price target of $126.01.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/06/gw-pharmaceuticals-plc-gwph-shares-gap-up-to-82-73.html
The stock’s 50-day moving average is $88.26 and its 200-day moving average is $80.50. The company’s market cap is $1.84 billion.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.21) by $1.15. The company earned $3.10 million during the quarter, compared to analysts’ expectations of $3.63 million. During the same quarter in the previous year, the company earned ($0.09) earnings per share. The firm’s quarterly revenue was down 73.3% compared to the same quarter last year. Equities research analysts expect that GW Pharmaceuticals PLC- will post ($4.52) EPS for the current fiscal year.
GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.
Receive News & Ratings for GW Pharmaceuticals PLC- Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com’s FREE daily email newsletter.